JAK inhibitors for the treatment of adult dermatomyositis: A pilot study

To the Editor: Dermatomyositis (DM) remains difficult to manage and novel therapies to improve outcome of patients with DM are needed. Increasing evidence suggests the key role of interferon pathway in DM, 1 Huard C. Gullà S.V. Bennett D.V. Coyle A.J. Vleugels R.A. Greenberg S.A. Correlation of cutaneous disease activity with type 1 interferon gene signature and interferon β in dermatomyositis. Br J Dermatol. 2017; 176: 1224-1230https://doi.org/10.1111/bjd.15006 Crossref PubMed Scopus (81) Google Scholar which may be inhibited in vitro by a JAK inhibitor (JAKinh). 2 Ladislau L. Suárez-Calvet X. Toquet S. et al. JAK inhibitor improves type I interferon induced damage: proof of concept in dermatomyositis. Brain J Neurol. 2018; 141: 1609-1621https://doi.org/10.1093/brain/awy105 Crossref PubMed Scopus (143) Google Scholar